Mauna Kea Technologies Elevates Pancreatic Cancer Awareness

This November, Mauna Kea Technologies is amplifying voices during Pancreatic Cancer Awareness Month. The company emphasizes early detection, using patient stories to spotlight their confocal laser endomicroscopy platform.

With a mere 13% five-year survival rate, the urgency for awareness is critical. Notably, most individuals are unaware of early pancreatic cancer symptoms, such as persistent pain and sudden-onset diabetes. Mauna Kea addresses this gap by showcasing how timely diagnosis can transform lives.

The Cellvizio® platform by Mauna Kea allows real-time cellular imaging, aiding accurate diagnosis, especially for those at high risk. This innovation underscores the importance of early detection in improving patient outcomes.

Collaboration with global healthcare professionals remains key to advancing endomicroscopy and enhancing patient care.